Bezafibrate

苯扎贝特

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameBezafibrate
Drug Alias Namebezafibrato苯紮贝特bezafibratum阿贝他益之特 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator activated receptor agonists
TargetsPeroxisome proliferator activated receptor
Therapy Area/IndicationsMitochondrial DiseasesHypertriglyceridemiaHypercholesterolemia +[4] 
Global Approved IndicationsHypertriglyceridemiaHypercholesterolemiaHyperlipidemia, Familial Combined
Approved Indications in ChinaHypertriglyceridemiaHypercholesterolemiaHyperlipidemia, Familial Combined
Original Approved Country/TerritoryJapan
Original Approved Date1978/01/01
Country/TerritoryUnited KingdomMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNipro Corp
China Registration ClassN/A

Develop Information

Active CompaniesNipro CorpExcella Gmbh
Inactive CompaniesNewcastle University
Active IndicationsHypertriglyceridemiaHypercholesterolemiaHyperlipidemia, Familial Combined
Inactive IndicationsMitochondrial Diseases

Other Information

ATC CodeC10AB02
Related LinksWikipediaDrugBankKEGG